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We report a patient in Japan infected with Cryptococ-
cus gattii genotype VGIIa who had no recent history of trav-
el to disease-endemic areas. This strain was identical to the 
Vancouver Island outbreak strain R265. Our results suggest 
that this virulent strain has spread to regions outside North 
America.
C
ryptococcus neoformans and C. gattii are closely re-
lated species of yeast; C. gattii was previously classi-
ﬁ  ed as C. neoformans var. gattii (1). Although both species 
cause pulmonary or central nervous system infections, they 
differ in their ecology, epidemiology, and pathobiology. C. 
neoformans is the most common Cryptococcus spp. world-
wide and mainly affects immunocompromised hosts. In 
contrast, C. gattii mainly affects immunocompetent hosts 
and often forms mass-like lesions (cryptococcomas).
Multilocus sequence typing can be used to divide this 
species into 4 molecular genotypes, VGI–VGIV, which 
differ in epidemiology and virulence (1,2). C. gattii was 
believed to be restricted to tropical and subtropical areas 
such as Australia, Southeast Asia, and South America (1). 
However, in 1999, a C. gattii infection outbreak occurred 
on Vancouver Island, British Columbia, Canada (3), which 
has a temperate climate.
During the Vancouver Island outbreak, most human, 
animal, and environmental isolates obtained belonged to 
VGIIa (major genotype, 90%–95% of isolates) and VGIIb 
(minor genotype, 5%–10% of isolates) (2,3). These strains 
have now spread to mainland British Columbia and the 
Paciﬁ  c Northwest region of the United States (1,4,5). The 
potential for further spread of this strain, particularly the 
VGIIa genotype, is a serious concern because it is highly 
virulent in mammals and can infect immunocompetent 
persons (2).
We report a case of cerebral cryptococcoma caused by 
C. gattii VGIIa (a strain identical to the Vancouver Island 
outbreak major genotype strain R265) in a patient from 
Japan who had no recent travel history to known disease-
endemic areas.
The Patient
In 2007, a 44-year-old man (sign painter) from Japan 
who was not infected with HIV came to the University of 
Tokyo Hospital with a 2-month history of headache and 
loss of right-sided vision in both eyes (right homonymous 
hemianopsia). He had had a diagnosis of hyperglycemia 3 
years before admission but had declined to seek medical 
treatment. His medical history was otherwise unremark-
able. He was an ex-smoker who rarely consumed alcohol 
and was not taking any prescription medications (includ-
ing corticosteroids or other immunosuppressive drugs). He 
had traveled to Guam in 1990 and Saipan in 1999 and had 
no other history of overseas travel. He reported exposure 
to his dog, and he did not spend time in wilderness areas. 
The patient often worked near construction sites in urban 
locations.
When hospitalized, the patient was afebrile and had 
stable vital signs. Physical examination showed agraphia 
(inability to write), anarithmia (inability to count numbers), 
right homonymous hemianopsia, and Romberg sign. Labo-
ratory evaluations showed increased glucose (367 mg/dL) 
and hemoglobin A1c (10.5%) levels. Results of a complete 
blood cell count and hepatic and renal function tests were 
within normal limits. Levels of electrolytes and C-reactive 
protein were also within normal limits. Results of a test for 
antibodies to HIV-1/2 were negative.
An enhanced brain magnetic resonance imaging scan 
showed a 4.4 × 4.1 × 3.3–cm lobulated mass in the left oc-
cipital lobe with surrounding edema. The lesion had low 
signal intensity on T1-weighted images, moderate signal 
intensity on T2-weighted images, and rim enhancement 
on T1-weighted images after administration of gadolinium 
(Figure). A chest computed tomography scan showed a 1.8 
× 1.2–cm nodule in the left lower lung (S8 segment).
The brain mass was completely resected because it 
was suspected to be a tumor. Pathologic evaluation of the 
resected specimen showed that the mass was a large ab-
scess containing encapsulated yeast. The yeast could be 
seen after staining with periodic acid–Schiff and Grocott 
methenamine silver stains. Specimen cultures were posi-
tive for Cryptococcus spp. and led to a diagnosis of cere-
bral cryptococcosis.
The patient was treated with liposomal amphotericin 
B (4 mg/kg/d for 3 weeks) and ﬂ  ucytosine (100 mg/kg/d 
for 3 weeks). A cerebrospinal ﬂ  uid (CSF) sample obtained 
by lumbar puncture soon after mass resection showed a 
slightly increased protein level but no leukocytosis or a low 
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negative results. Cryptococcal antigen titers were >512 in 
serum and 64 in CSF.
After 3 weeks of induction therapy, the patient received 
consolidation and maintenance therapy (oral ﬂ  uconazole, 
400 mg/d) for 1 year. The pulmonary nodule decreased in 
size after antifungal treatment, suggesting that this lesion 
was a pulmonary cryptococcoma. At the 1-year follow-up 
visit, the cerebral cryptococcoma had not recurred, and the 
pulmonary nodule had disappeared.
The cryptococcal  strain isolated from the brain was 
identiﬁ  ed as serotype B by slide agglutination test (6) and 
identiﬁ  ed as C. gattii by rRNA gene sequence analysis 
(7). Eleven unlinked loci (SXI1, IGS, TEF1, GPD1, LAC1, 
CAP10, PLB1, MPD1, HOG1, BWC1, and TOR1) analyzed 
by multilocus sequence typing, according to the method of 
Fraser et al. (2), were identical to those of the Vancouver 
Island major genotype strain R265 (genotype VGIIa) (Ta-
ble) (2,8,9). MICs of this isolate were 0.125, 0.5, 1.0, and 
0.011 μg/mL for amphotericin B, ﬂ  ucytosine, ﬂ  uconazole, 
and itraconazole, respectively.
Conclusions
Japan has not been considered a C. gattii–endemic 
area. There have been only 2 reports of C. gattii infections 
in Japan; both infections apparently originated in Austra-
lia (10,11). Retrospective surveillance studies found no 
evidence of C. gattii infection or colonization in Japan (12; 
Ministry of Health, Labor and Welfare of Japan, 2003, un-
pub. data). Although the source of the infection in the pa-
tient reported here has not been identiﬁ  ed, it appears to have 
originated in Japan. Infections with C. gattii have not been 
reported in the places the patient had visited (Guam and 
Saipan) (13,14). Analysis of persons who traveled to Van-
couver Island indicated that the median incubation period 
of C. gattii infection is 6–7 months (range 2–11 months) 
(13), although an incubation period of 13 months has been 
reported for 1 patient (14).
C. gattii genotype VGIIa may have been present in the 
Paciﬁ  c Northwest region of the United States long before 
the Vancouver Island outbreak (2,4). However, no human 
cases were identiﬁ  ed in the United States until January 
2006 (4,5). Genotype VGIIa has now spread from Van-
couver Island to mainland British Columbia and the Paciﬁ  c 
Northwest region of the United States, possibly because of 
human activity or animal migration (1). However, this gen-
otype has not been reported in any other region, although 
similar isolates have been obtained from South America (1) 
and from patients who had traveled to affected areas (1,8). 
Thus, our ﬁ  ndings indicate possible global dispersal of this 
strain.
Our results suggest that C. gattii VGIIa genotype may 
be spreading. In North America, this genotype has been 
isolated from various environmental specimens such as tree 
surfaces, soil, water, and air (1,4). Soil is believed to be 
a major potential reservoir of this organism (1,15). Thus, 
ecologic and environmental studies on C. gattii in Japan 
are needed to determine likely reservoirs and to improve 
understanding of C. gattii epidemiology. Although many 
clinical laboratories in Japan currently do not differentiate 
between C. neoformans and C. gattii infections, identiﬁ  ca-
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Figure. Postcontrast T1-weighted magnetic resononance image 
of the brain of a 44-year-old man with cerebral cryptococomma in 
Japan, 2007, showing a rim-enhancing lobulated mass (lower right) 
with surrounding edema in the left occipital lobe.
Table. Multilocus sequence typing profiles of 2 Cryptococcus gattii strains, Japan, 2007* 
Strain
Multilocus sequence typing profile† 
SXI1Į IGS TEF1 GPD1 LAC1 CAP10 PLB1 MPD1 HOG1 BWC1 TOR1
JP01 18 4 7 1 4 1 1 5 1 1 1
R265 18 4 7 1 4 1 1 5 1 1 1
*JP01, strain from Japan (patient in this study); R265, Vancouver Island genotype VGIIa strain. 
†GenBank accession nos. for multilocus sequencing typing alleles: SXI1Į_18, DQ096308; IGS_4, DQ096314; TEF1_7, DQ096364; GPD1_1, DQ096377; 
LAC1_4, DQ096400; CAP10_1, DQ096416; PLB1_1, DQ096343; MPD1_5, DQ096334; HOG1_1, DQ096456; BWC1_1, DQ096428; TOR1_1,
DQ096470.C. gattii infection in Man, Japan, 2007
tion of cryptococcal isolates to the species level, especially 
in apparently immunocompetent patients, is needed.
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